Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Buying opportunity - Market maker out of business -- Ignore unavailable to you. Want to Upgrade?

To: Master (Hijacked) who wrote (318)	2/24/1998 4:40:00 AM
From: Master (Hijacked)	Read Replies (1) \| Respond to of 472

I'm taking FLEM off my "A" list. Its going from a winner to a loser. Latest news reveals big problems- looks like they won't be seeing any revenues until the middle of the next millenium, and will have to PAY to develop their own products, and they're basically starting from scratch: biz.yahoo.com Thats NOT what they said earlier, when they said they would be targeting HIGH VOLUME OTC medications already approved by the FDA for QUICK REVENUES and getting TOTAL FUNDING from major pharmaceutical companies- from SEC docs: "The Company has initially identified approximately fifty (50) presently marketed drugs that meet the Company's criteria for its drug delivery systems. The Company will concentrate its product development activities on those pharmaceuticals with significant prescription or OTC sales. The Company believes that applying a novel application delivery system to existing drugs involves less cost, time and risk than developing and commercializing a new chemical entity. The Company believes that there is significant opportunity to combine its delivery systems with existing pharmaceuticals to expand the market for an existing drug, differentiate a product from a generic or brand name competition, and possibly create new markets. In light of the material expense and delays associated with independently developing and obtaining approval of pharmaceutical products, the Company will only continue to develop such products through collaborative arrangements with major pharmaceutical companies, which will fund that development. To date, the Company has signed two such development agreements with major pharmaceutical companies. "